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Abstract
Background: Pyruvate kinase (PK) deficiency, causing hemolytic anemia, has been associated to malaria protection and its
prevalence in sub-Saharan Africa is not known so far. This work shows the results of a study undertaken to determine PK
deficiency occurrence in some sub-Saharan African countries, as well as finding a prevalent PK variant underlying this
deficiency.
Materials and Methods: Blood samples of individuals from four malaria endemic countries (Mozambique, Angola, Equatorial
Guinea and Sao Tome and Principe) were analyzed in order to determine PK deficiency occurrence and detect any possible
high frequent PK variant mutation. The association between this mutation and malaria was ascertained through association
studies involving sample groups from individuals showing different malaria infection and outcome status.
Results: The percentage of individuals showing a reduced PK activity in Maputo was 4.1% and the missense mutation
G829A (Glu277Lys) in the PKLR gene (only identified in three individuals worldwide to date) was identified in a high
frequency. Heterozygous carrier frequency was between 6.7% and 2.6%. A significant association was not detected between
either PK reduced activity or allele 829A frequency and malaria infection and outcome, although the variant was more
frequent among individuals with uncomplicated malaria.
Conclusions: This was the first study on the occurrence of PK deficiency in several areas of Africa. A common PKLR mutation
G829A (Glu277Lys) was identified. A global geographical co-distribution between malaria and high frequency of PK
deficiency seems to occur suggesting that malaria may be a selective force raising the frequency of this 277Lys variant.
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Introduction
Infectious diseases have been one of the major causes of
mortality during most of human evolution. For many diseases,
mortality and hence reproductive success are influenced by certain
individual genotype. Consequently, some aspects of modern
patterns of human genetic diversity should have been determined
by diseases dating from prehistoric times [1]. The clearest example
are provided by malaria, which even now affects 500 million
people each year and kills some two million. The selective pressure
that malaria has imposed to human populations has been reflected
in dozens of molecular variants described as protective against the
infection and disease [2–4]. Of these, the most well studied and
widely accepted are probably the sickle cell allele (hemoglobin
HbS allele), a and b thalassemias and glucose-6-phosphate (G6PD)
deficiency (alleles A and A-), all showing an extensive overlap of
geographical distribution and exceptionally high frequencies in
malaria endemic regions.
Pyruvate kinase (PK) deficiency, caused by mutations in the
pyruvate kinase, liver and RBC (PKLR) gene (chromosome 1q21)
is one of the most recently described erythrocyte abnormalities
associated to malaria. Evidences of its protective effect were
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obtained both in murine models [5] and in Plasmodium falciparum in
vitro cultures using human PK-deficient blood [6,7]. Also,
population studies showed that a selective pressure is shaping the
PKLR genomic region in individuals from malaria endemic
countries (Cape Verde, Angola and Mozambique), being malaria
infection the most likely driving force [8,9].
PK catalyzes the conversion of phosphoenolpyruvate (PEP) into
pyruvate with the synthesis of ATP in the last step of glycolysis.
PEP and pyruvate are involved in a great deal of energetic and
biosynthetic pathways and the regulation of PK activity has
proven to be of great importance for the entire cellular metabolism
[10]. PK deficiency, worldwide distributed, is the most common
enzyme abnormality in the erythrocyte glycolytic pathway causing
hereditary chronic nonspherocytic hemolytic anemia. It is
transmitted as an autossomal recessive trait and clinical symptoms
usually occur in homozygotes and in compound heterozygotes for
two mutant alleles. The clinical phenotype is heterogeneous,
ranging from a mild chronic hemolytic anemia to a severe anemia
presenting at birth and requiring exchange transfusion [11].
High frequencies of PK deficiency have not yet been recorded
in malaria endemic areas but a systematic analysis has never been
performed. Considering the previous knowledge of co-distribution
between malaria endemicity and protective polymorphisms, we
questioned if a PK variant could be exceptionally prevalent in
malaria endemic areas. Therefore, the aims of the present study
were: i) to determine PK deficiency occurrence in sub-Saharan
African countries, ii) to assess frequency of PK variants underlying
this deficiency, iii) to investigate possible associations between PK
deficiency and malaria infection.
Materials and Methods
Sampling
This study is based on the molecular analysis of six sets of blood
samples collected in four sub-Saharan African areas – Mozam-
bique, Angola, Equatorial Guinea and Sao Tome and Principe
(see Figure 1) - and in a malaria non-endemic area – Portugal
(Europe).
In this study, 296 unrelated whole blood samples from
individuals who attended to the Central Hospital of Maputo
(Mozambique) between September and December 2008 were
analyzed: 144 from children (6 months to 14 years-old) who
presented to the Emergency Services of the Pediatric Department
with some kind of complaint, and 152 from healthy blood donor
adults (16 to 65 years-old) who presented to the Blood Bank. In
order to increase the sample size of the set with a malaria outcome
characterization, an additional group of 151 DNA samples
extracted from blood samples collected from 3 months to 15
years-old children in Mozambique [9] was also genotyped.
In the Pediatric Department, blood was collected by venous
puncture after the clinician examination but before the adminis-
tration of any anti-malarial drug and/or blood transfusion. The
registration of symptoms, axillary temperature and hemoglobin
level was done for all individuals. Children who had received a
blood transfusion in the last six months were excluded from the
study. Anemic and Plasmodium infection status were considered at
collection time. In the Blood Bank, the blood samples were
randomly collected from blood donors. In the admission, a
solubility test for rapid detection of hemoglobin S (adapted from
Loh [12]) was performed in order to exclude allele S carriers. After
blood collection in a tube, a blood spot in a filter paper was
prepared from each sample for later subsequent DNA extraction
by a standard phenol-chloroform method.
In addition to these samples from Mozambique, a set of 343
DNA samples from malaria-infected and non-infected unrelated
individuals, which were already available from other studies, were
also analyzed: 164 from Angola [9], 38 from Equatorial Guinea
[13] and 67 from Sao Tome and Principe [14]. Finally, 74 samples
from non-infected Portuguese individuals from all age groups were
used as control samples [8]. Overall, 790 samples were analyzed.
Ethics statement
Regarding the survey in Mozambique, the human isolates
collection was approved by local Ethical Committee (Comite´
Nacional de Bioe´tica para a Sau´de, Health Ministry of Mozam-
bique, IRB 00002657, ref. 226/CNBS/08) and IHMT (Conselho
de E´tica do Instituto de Higiene e Medicina Tropical, CEIHMT,
14-2011-PN). A detailed work plan, questionnaires and informed
consent forms were submitted to the Ethical Committees of the
participant institutions in the study, which approved the survey.
Each individual and parent/tutor of the children was informed of
the nature and aims of the study and was told that participation
was voluntary; written informed consent was obtained from each
person (or parent/tutor). Blood sample collection followed strict
requirements set by the Ethical Committees: blood samples from
children who attended to the Pediatric Department were the
remaining volume of the samples previously collected for the
medical diagnosis; in the Blood Bank, during the blood donation, a
small volume was put aside in a tube. In this way, no extra blood
collection was needed and the patient, blood donor and the
routine health services were not significantly disturbed. All ethical
aspects related with the other sets of samples collected in previous
studies, are described in the respective reports [8,9,13,14].
Plasmodium infection and malaria outcome groups
In the Central Hospital of Maputo, the rapid test OptiMAL-IT
(DiaMed, Switzerland) was used for malaria diagnosis in all the
patients with suspicion of malaria infection, and a blood smear was
prepared for microscopic visualization to confirm diagnosis; later,
all samples were amplified by Polymerase Chain Reaction (PCR),
using Plasmodium species specific primers [15].
Malaria outcome was defined as follows: (i) Severe Malaria
(SM): positive PCR for any species of Plasmodium, fever (i.e. axillary
temperature $37,5uC), hemoglobin level of Hb#5 g/dL and/or
any of these symptoms: coma, prostration or convulsions; (ii)
Uncomplicated Malaria (UM): positive PCR for any Plasmodium
species, fever and hemoglobin level of Hb.5 g/dL; and (iii)
Asymptomatic Infection (AI): positive PCR for any Plasmodium
species in the absence of fever (i.e. axillary temperature ,37,5uC)
or other symptoms of clinical illness; (iv) No infection (NI):
negative PCR and absence of fever or other symptoms of clinical
illness.
Based on malaria infection and symptoms data, the 144 samples
from the Pediatric Department of Central Hospital of Maputo
collected in 2008 were organized in the following malaria outcome
groups: SM (18 samples); UM (27 samples) and NI (99 samples).
The 152 samples from the Blood Bank were organized in the
following groups: AI (4 samples) and NI (148 samples). Outcome
groups were also defined using the same criteria for the set of
isolates from Angola (43 SM, 43 UM, 37 AI and 41 NI) and for the
set of isolates previously collected in Mozambique (52 SM, 97 UM
and 2 NI), both described in Machado et al. [9]. In total, we had
611 samples with malaria infection and outcome characterization -
459 samples from children (113 SM, 167 UM, 37 AI and 142 NI)
and 152 samples from adults (4 AI and 148 NI).
PK Deficiency in Sub-Saharan Africa
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Determination of PK activity
PK activity was measured in lyzed erythrocytes from all the 296
fresh blood samples (after plasma and buffy coat strict removal)
collected in Mozambique in 2008, with an enzymatic assay
adapted from Beutler [16], according to the instructions of the kit
‘‘Determination of pyruvate kinase (EC 2.7.1.40) in erythrocytes
hemolysate or serum/heparinized plasma’’ (Instruchemie, The
Netherlands). The enzymatic reactions were running at room
temperature. A PK-deficient and a normal control were used in
each assay to validate the activity values and to classify the samples
within the following phenotypes: normal, intermediate or deficient
activity.
Identification of a PK variant underlying PK-reduced
activity
Samples with a PK activity value less than or equal to 75% of
the normal control sample activity were analyzed by the Single
Strand Conformational Polymorphism (SSCP) method (described
in Manco et al. [17]) in order to find a mutation associated with
this phenotype. The promoter region and eleven exons of the
PKLR gene were amplified with specific primers (see Table S1,
supporting information) and run in an acrylamide-bisacrylamide
gel (10%), together with a wild-type amplicon, to detect differences
in migration patterns caused by an alteration in DNA chain
composition (exon 2 was not analyzed since it is specific for the
hepatic isoenzyme). The amplification conditions were: initial
denaturation at 94uC for 5 minutes, followed by 35 cycles of 94uC
for 45 seconds, a specific annealing temperature for 45 seconds
(see Table S1), and 72uC for 1 minute, with a final extension at
72uC for 5 minutes. The samples with a different migration
pattern were further analyzed by automatic DNA sequencing
(Macrogen Inc., Korea). The exon 7, in which a mutation was
identified, was then amplified in all samples from all groups by
PCR with the specific primers and conditions indicated in Table
S1 and the amplicons were sequenced (Macrogen Inc., Korea).
Statistical analysis
The association between alleles and malaria outcome groups
was assessed by Pearson’s chi-square tests and Fisher’s exact test,
this latter considered when there were a few cases in each
comparison group (less than five), using the Simple Interactive
Statistical Analysis software (SISA) [18]. Odds ratios (OR) and
95% confidence intervals (CI) were also estimated using SISA.
Arlequin 3.1 software [19] was used to determine allele
frequencies, population pairwise FST (to test for differentiation
between populations), expected and observed values of heterozy-
gosity and to perform Hardy–Weinberg equilibrium tests.
Prediction of the possible impact of the amino acid substitution
on the structure and function of the human PK protein was
performed with the Polyphen software [20]. Finally, PyMol
software [21] was used for the 3D structure simulation of the
wild type and mutant variants.
Figure 1. Geographic location of the countries Mozambique, Angola, Sao Tome and Principe, Equatorial Guinea (Africa), Pakistan
(Asia) and Portugal (Europe).
doi:10.1371/journal.pone.0047071.g001
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Results
PK deficiency screening in Maputo, Mozambique
Ninety-eight from the 144 samples collected in the Pediatric
Department (68%) in Mozambique in 2008 were from children
with a hemoglobin concentration ,9 g/dL (considered anemic)
and 41 samples (28.5%) were infected with P. falciparum. Nineteen
of the infected individuals were also anemic. Four (2.6%) of the
152 samples from the adult blood donors in Blood Bank showed
an asymptomatic infection with P. falciparum (see Table 1)
From the 296 samples set, 12 (4.1%) presented PK activity
values between 39% and 75% of the normal control activity
(established in an average of 3.2 U/g Hb) (see Table 2): 8 from the
Blood Bank (5.3%) and 4 from the Pediatrics (2.8%). They were all
classified as intermediate activity phenotype. From the 98 samples
with a hemoglobin level ,9 g/dl (Pediatric Department), only 3
(3.1%) had a PK reduced activity.
Identification of a PK variant underlying PK-reduced
activity
A migration pattern alteration was observed in the amplicon of
exon 7 of 5 out of 12 samples with low activity (41.7%) by SSCP
(see Figure 2): 4 from blood donors and 1 from Pediatrics.
Sequencing of these 5 amplicons revealed a G.A substitution in
all of them, being in homozygosis (A/A) in one sample. This is a
non-synonymous mutation located in the nucleotide 829 of the PK
mRNA sequence originating an alteration of the amino acid 277
of the PK protein: a glutamic acid (Glu, coded by GAG) is
replaced by a lysine (Lys, coded by AAG). When this mutation was
searched in all the other 284 samples with normal activity, it was
detected in heterozygosis in 16 samples: 7 from children and 9
from blood donors. Overall, 21 samples (7.1%) had the 829A allele
that displayed a frequency of 3.7%.
No association was found between the 829A allele and anemia
(2.7–9 g/dL Hb). Conversely, a strong association was found
between the allele 829A and PK deficient activity: x2 = 14.38
(P,0.00), OR = 5.58 (95% CI: 2.07–15.03). Of the 6 samples with
the lowest PK activity values (between 39% and 47% of the normal
activity), 5 had the mutation. All the 6 other samples with an activity
between 47% and 75% of the normal activity were wild type.
As visualized in the 3D PK structure simulation (see Figure 3),
this 277 residue is exposed, showing a peripheral position. The
prediction of the substitution Glu277Lys effect on the structure
and function of the human protein PK was ‘‘Possibly Damaging’’
(score of 0.90) supporting the previous OR result and suggesting
that this mutation is likely to be non-functional.
Searching the mutation G829A in other African malaria
endemic areas
The mutation G829A was found in the other three African
countries, always in heterozygosis: in 11 samples from Angola
(6.7%), 1 sample from Equatorial Guinea (2.6%) and 2 samples
from Sao Tome and Principe (3.0%). Allele 829A frequencies were
3.4%, 1.3% and 1.5%, respectively. In the Mozambican group
from 2005, the frequency of individuals heterozygous for 829A
was 5.3%, giving an allele frequency of 2.6%. The mutation was
not found in the control group from Portugal. Considering all the
Mozambican 447 samples, a frequency of carrier individuals of
5.8% and 829A allele frequency of 3.0% were estimated.
The observed genotype frequencies (829GG, 829AG and
829AA) were according to Hardy-Weinberg expectations for all
populations (P = 0.40 in Mozambique; P = 1.00 in Angola,
Equatorial Guinea and Sao Tome and Principe). Estimates of
FST were non-significant between all pairs of African populations
(FST#0.00 for all) (P = 1.00 for Mozambique vs. Angola; P = 0.50
for Mozambique vs. Equatorial Guinea; P = 0.30 for Mozambique
vs. Sao Tome and Principe; P = 0.51 for Angola vs. Equatorial
Guinea; P = 0.35 for Angola vs. Sao Tome and Principe; and
P = 1.00 for Equatorial Guinea vs. Sao Tome and Principe).
Association among PK-reduced activity, the mutation
G829A and malaria infection/outcome
Six-hundred and eleven DNA samples belonging to individuals
characterized for their infection and malaria disease outcome
status were analyzed: 459 samples from children (113 SM, 167
UM, 37 AI and 142 NI) from Angola and Mozambique and 152
samples from adults (4 AI and 148 NI), from Mozambique. No
significant differentiation between samples from Angola and
Mozambique were observed, so all samples together were
considered for this analysis.
Allele 829A frequencies were as follows (see Table 3): in children,
3.1% in SM, 3.3% in UM, 2.7% in AI and 2.5% in NI; in adults
4.4% in NI. In terms of malaria infection in children, allele A
frequencies were 3.2% in infected and 2.5% in non-infected. In
adults, this analysis in terms of infection was not considered due to
the low number of infected individuals. Although the mutation
frequency was higher in uncomplicated (UM) than in severe malaria
(SM) group, no significant association was observed between 829A
allele and disease outcome (x2 = 0.02, P = 1.00; OR = 1.07, 95% CI:
0.41–2.80). No significant association was found either between
829A allele and infection (x2 = 0.33, P = 0.57; OR = 1.29, 95% CI:
0.54–3.08) or between PK deficient activity (low enzyme activity)
and infection (P = 0.30), though 11 from the 12 samples with PK
reduced activity were non-infected.
Table 1. PK activity, anemia and Plasmodium infection status in the sample set from Maputo, Mozambique (2008).
Pediatrics Blood Bank Total
Age Group Children (6 months–14 years old); with
some complaint
Adults (16–65 years old); healthy
blood donors
6 months–65 years old
Nr of samples 144 152 296
Low PK activity (39–75% of control) 4 (2.8%) 8 (5.3%) 12 (4.1%)
Anemia (Hb,9 g/dL) 98 (68.1%) n.d. n.d.
Plasmodium infection 41 (28.5%) 4 (2.6%) 45 (15.2%)
Anemia+Infection 19 (13.2%) n.d. n.d.
n.d.: not determined.
doi:10.1371/journal.pone.0047071.t001
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Discussion
This is the first study aimed at determining PK deficiency
occurrence as well as at studying a potential widespread PKLR
mutation in the African continent.
In the first instance, PK deficiency was studied in samples from
Maputo, Mozambique, measuring PK activity in anemic individ-
uals, as this is described as a symptom of the disease. However,
anemia was neither associated to PK reduced activity nor 829A
allele. The overall prevalence rate of PK reduced activity was
4.1% in the study population (5.3% from blood donors and 2.8%
from children). Although children samples were, most of them,
clinical cases with a considerable anemic status, a higher PK
deficiency prevalence was not found in these samples and no
association was detected between PK low activity and anemia. In
this regard, a study carried in 2002 revealed that 74% of the
children under five and 50% of the women in reproductive age
from Mozambique was anemic [22], showing that anemia is not a
proper indicator of erythrocyte deficiencies in developing coun-
tries.
The missense mutation G829A (Glu277Lys) was identified in
41.7% of Mozambican PK deficient isolates with a strong
association with reduced activity phenotype. This mutation was
then searched in additional Mozambican samples and other sub-
Saharan regions and the 829A allele was detected in all of them at
allele frequencies between 1.3% (in Equatorial Guinea) and 3.4%
(in Angola). The allele 829A was not present in the Portuguese
samples. Although two African groups could be established
according to these frequencies (Angola and Mozambique with
higher frequencies vs. Equatorial Guinea and Sao Tome and
Principe with lower frequencies), FST values were not significantly
different between them. These differences may be explained by
sample size bias (447 samples from Mozambique and 164 from
Table 2. Samples with a reduced PK activity (between 39 and 75% of the normal control) and respective infection status and
malaria outcome and 829 locus genotype.
PK Activity U/g Hb
# Sample Assay Activity Average Control N Average/Control N Control DEF
Inf/Malaria
outcome 829G/A
1 BS_128 1 1.69 1.69 3.48 0.49 0.85 NI GG
2 BS_176 1 1.88
BS_176 2 1.93 1.91 3.48 0.55 0.85 NI GG
3 BS_197 1 1.56
BS_197 2 1.34 1.45 3.48 0.42 0.85 NI GA
4 BS_199 1 1.73
BS_199 2 0.99 1.36 3.48 0.39 0.85 NI GA
5 BS_212 1 1.85
BS_212 2 1.43 1.64 3.48 0.47 0.85 NI GA
6 BS_220 1 1.35
BS_220 2 1.52 1.44 3.48 0.41 0.85 NI GG
7 BS_230 1 1.46
BS_230 2 1.59 1.53 3.48 0.44 0.85 NI AA
8 BS_327 1 1.74
BS_327 2 1.96 1.85 3.48 0.53 0.85 NI GG
9 N_1159 1 1.93
N_1159 2 2.27 2.10 2.91 0.72 0.73 NI GG
10 N_1391 1 2.19 2.19 2.91 0.75 0.73 NI GG
11 N_1464 1 1.69 1.69 2.91 0.58 0.73 NI GG
12 O_2341 1 1.35 1.35 2.91 0.46 0.73 SM GA
BS: samples collected in the Blood Bank; O and N: samples collected in the Department of Pediatrics; Inf/Malaria outcome: infection status and malaria outcome; 829G/A:
829 genotype; NI: non-infected; SM: severe malaria.
doi:10.1371/journal.pone.0047071.t002
Figure 2. SSCP results showing a migration pattern alteration
in the exon 7 amplicons caused by the G829A substitution
(10% acrylamide-bisacrylamide gel) - samples at the extremes
(wild type isolate in the middle).
doi:10.1371/journal.pone.0047071.g002
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Angola were processed against 38 from Equatorial Guinea and 64
from Sao Tome and Principe) or design bias (isolates from
Mozambique and Angola were obtained in hospital-based studies,
whereas the others were collected in households by active search).
In addition, genetic substructure among geographic regions
cannot be excluded as a hypothesis for this disparity. Differences
in malaria selective pressure are not a probable cause, since it has
probably been similar in all these regions in the past.
Prevalence of PK deficiency seems to vary greatly among ethnic
groups and geographic regions, as well as the mutations in the
PKLR gene. Some authors have estimated a prevalence of
1:20 000 in the general white population [23]. In Europe, an
incidence of 3.3 per million has been reported in the north of
England [24], and a prevalence of 0.24% and 1.1% have been
described in Spain [25] and Turkey [26], respectively. In Asia, the
frequency of PK deficiency among the Hong Kong Chinese
population was ,0.1% [27] whilst among the south Iranian
population was 1.9% [28]. In Saudi Arabia, a prevalence of 3.12%
was registered in newborns [29]. These studies were all based in
PK activity measurements. The estimated mutant allele frequen-
cies of common variants generally vary between 0.2 and 0.8% [23]
with the highest heterozygous prevalence described so far in Saudi
Arabia (6%) [28,30] and Hong Kong (3.4%) [31]. However, these
last allele frequencies were not calculated from mutation
genotyping but only estimated from the Beutler’s screening
qualitative procedure and enzyme assay [16], which result in less
reliable estimates of heterozygosity. Moreover, consanguinity is
extremely high in Saudi Arabia, exceeding 80% in some regions
[29], which tends to bias the results.
The PK deficiency recorded in Mozambique (4.1%) and 829GA
heterozygous prevalence (2.6–6.7%) determined from unrelated
individuals from sub-Saharan populations is, to our knowledge, the
highest estimated worldwide so far. We initially hypothesized that
this would be the result of a strong malaria pressure, but a significant
association between both PK low activity and 829A and malaria
infection and outcome was not found. However, only 12 samples
were available for testing a possible effect of low enzyme activity on
severity of malaria and 20 samples for testing a possible effect of
829A allele meaning that larger numbers are required to formally
conclude. Moreover, since this was a cross-sectional study, infection
and malaria outcome groups were established according to a
malaria phenotype in a specific time point (the collection day), that
may not accurately reflect the true individual phenotype. Never-
theless, there was higher mutation prevalence in the uncomplicated
malaria group supporting that further analysis is essential to
complete the present study.
The Glu277Lys mutation here identified has been previously
reported in the PKLR mutation database [32] and has recently
been described [30] in only two individuals: one from the
Mandenka ethnic group (one of the largest ethnic groups in West
Africa) and other from the Brahui ethnic group from Pakistan,
showing that is also present in Middle East. Since the haplotypes
that include this mutation in these two individuals are different, it
was suggested that it has arisen separately. In Pakistan, as in sub-
Saharan countries, malaria continues to be a major public health
problem. Both P. falciparum and Plasmodium vivax are widely
distributed and the estimated number of annual malaria episodes
in this country is 1.5 million [33].
The simulation of this Glu277Lys substitution on the human
PK protein suggested that this mutation is likely to be non-
functional. This residue is extremely well conserved and the result
complies with the prediction from SIFT from a previous work
[30]. Probably, the charge change (Glu is negatively whereas Lys is
positively charged) at an exposed site alters the enzyme action.
Considering this result together with the knowledge about PK
deficiency that clinical symptoms usually occur in homozygotes for
a mutant PKLR allele, it was surprising to find that the 829AA
genotype belonged to a healthy blood donor without anemia
Figure 3. Location of the amino acid 277 in the PK protein and
simulation of the 3D wild type 277Glu and mutant 277Lys PK
variants structure with the software PyMol. a) Peripheral position
of the amino acid 277 (domain A); b) Wild type variant 277Glu; c)
Mutant variant 277Lys.
doi:10.1371/journal.pone.0047071.g003
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symptoms, with a PK activity of 0.44 with regard to the normal
control. In this case we were expecting an activity similar to the
deficient control sample (0.8 U/g Hb). However, the results
obtained regarding PK activity must carefully be considered since
the range of values obtained in Mozambique was narrow, far
below the values expected with the use of the kit and generally
obtained in other labs (about 3.7–8.2 U/g Hb at 25uC and about
7.4–16.4 U/g Hb at 37uC), with a thin gap between normal and
reduced activity. This can be explained by the lower room
temperature in the lab (about 20uC), when compared to those
generally maintained in this procedure (25uC or 37uC). Yet, the
procedure was efficient since it was possible to identify samples
with reduced activity. Actually, there was no direct relation
between the genotype and phenotype: although a significant
association between 829A and a reduction in the enzyme activity
was found out (and the samples with the lowest activity were those
ones with the 829A allele), the phenotype of allele A carriers was
highly variable with a large number of individuals within normal
PK activity range. A previous study emphasizes the difficulty in
predicting the consequences of mutations simply from the location
and the nature of the target residues [10]: the clinical manifes-
tations of a genetic disease reflect the interactions of a variety of
physiological and environmental factors, including genetic back-
ground, concomitant functional polymorphisms of other enzymes,
posttranslational or epigenetic modifications, ineffective erythro-
poiesis and differences in splenic function, and do not solely
depend on the molecular properties of the altered molecule.
To conclude, a geographical co-distribution between malaria
and PK-deficiency seems to occur: the Middle East and sub-
Saharan Africa are the regions with the highest PK deficiency
prevalence described so far, as determined in the present study.
These are regions with a strong malaria pressure, suggesting that
malaria may be an agent of contribute to the selection of PK
deficiency variants in these regions. Conversely, the prevalence of
PK deficiency is extremely low in the general white populations.
Moreover, some of the genes that confer resistance to malaria are
among the most variable genes in the human genome [4] and this
is the case for PKLR gene, which presents more than 180
mutations and 8 polymorphic sites [11].
Additional studies with a larger sampling effort including
longitudinal malaria clinical history characterization and a search
of the variant 277Lys in other malaria endemic regions will be
conducted to clarify the results in this survey.
Supporting Information
Table S1 List of primers and annealing temperatures
(a.t.) used in the amplification of PKLR promoter (Prom)
and coding regions by PCR.
(DOCX)
Acknowledgments
Authors would like to express their gratitude to Dra. Umbelina Rebelo,
Dra. Celeste Bento and Dr. Luı´s Relvas from the Hematology Department,
Centro Hospitalar de Coimbra, as well as to Dra. Isabel Abergaria and the
technicians from the Clinical Chemistry Lab, Instituto Nacional de Sau´de
Dr. Ricardo Jorge (Portugal) for all their help concerning the methodol-
ogies and protocols for PK assays. The authors also want to thank to Joa˜o
Rodrigues for doing the 3D structure simulation of the PK variants with
PyMol software. Deep appreciation for the contribution of D. Violeta and
Sa´bado from the Pediatric Lab and all the technicians from the Blood Bank
(Central Hospital of Maputo, Mozambique) for collecting blood samples
and to all volunteers that agreed in participate in the present study. Very
special thanks to Natacha, Anto´nia, Dida and Juliana, Filipa and Pedro for
their unconditional support during the stay at Mozambique.
Author Contributions
Conceived and designed the experiments: APA. Performed the experi-
ments: PM CG CM LM. Analyzed the data: PM APA. Contributed
reagents/materials/analysis tools: APA LM AA. Wrote the paper: PM
APA. Did the field work at Mozambique (2008): PM GS JL LS NF SC.
Processed the biological material and data collection in Mozambique,
Angola, Sao Tome and Principe, Equatorial Guinea and Portugal,
respectively: NF JM JP JC AA. Contributed with a critical review of the
paper: AA CM JC JP LM LR SC VdR.
References
1. Jobling MA, Hurles ME, Tyler-Smith C (2004) Human evolutionary genetics:
origins, peoples and disease. Garland Science, New York.
2. Verra F, Mangano VD, Modiano D (2009) Genetics of susceptibility to
Plasmodium falciparum: from classical malaria resistance genes towards genome-
wide association studies. Parasite Immunol 31: 234–253.
3. Allison AC (2009) Genetic control of resistance to human malaria. Curr Opin
Immunol 21: 499–505.
4. Hedrick PW (2011) Population genetics of malaria resistance in humans.
Heredity 107: 283–304.
5. Min-Oo G, Fortin A, Tam MF, Nantel A, Stevenson MM, et al. (2003) Pyruvate
kinase deficiency in mice protects against malaria. Nat Genet 35: 357–362.
Table 3. Allele 829A frequencies in infection and malaria outcome groups.
CHILDREN1 ADULTS2
Infection/Clinical group Samples 829A carriers 829A frequency Samples 829A carriers 829A frequency
SM 113 7 (6.2%) 3.1% 0 0 (0%) 0 (0%)
UM 167 11 (6.6%) 3.3% 0 0 (0%) 0 (0%)
AI 37 2 (5.4%) 2.7% 4 0 (0%) 0 (0%)
NI 142 7 (4.9%) 2.5% 148 133 (8.8%) 4.7%
INF (SM+UM+AI) 317 20 (6.3%) 3.2% 4 0 (0%) 0 (0%)
TOTAL 459 27 (5.9%) 2.9% 152 13 (8.6%) 4.6%
1Samples from children well characterized for infection and malaria outcome status from Maputo, Mozambique (collected within this study and in a previous one [9])
and from Angola (collected previously [9]) who attended to the Pediatrics Department.
2Samples from adult blood donors from Maputo, Mozambique (collected within this study).
3Including one 829AA homozygote (the only one identified in the study).
SM: severe malaria; UM: uncomplicated malaria; AI: asymptomatic infection; NI: non-infected; INF: infected.
doi:10.1371/journal.pone.0047071.t003
PK Deficiency in Sub-Saharan Africa
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e47071
6. Ayi K, Min-Oo G, Serghides L, Crockett M, Kirby-Allen M, et al. (2008)
Pyruvate kinase deficiency and malaria. N Engl J Med 358: 1805–1810.
7. Durand PM, Coetzer TL (2008) Pyruvate kinase deficiency protects against
malaria in humans. Haematologica 93: 939–940.
8. Alves J, Machado P, Silva J, Gonc¸alves N, Ribeiro L, et al. (2010) Analysis of
malaria associated genetic traits in Cabo Verde, a melting pot of European and
sub Saharan settlers. Blood Cells Mol Dis 44: 62–68.
9. Machado P, Pereira R, Rocha AM, Manco L, Fernandes N, et al. (2010)
Malaria: looking for selection signatures in the human PKLR gene region.
Br J Haematol 149: 775–784.
10. Valentini G, Chiarelli LR, Fortin R, Dolzan M, Galizzi A, et al. (2002) Structure
and function of human erythrocyte pyruvate kinase. Molecular basis of
nonspherocytic hemolytic anemia. J Biol Chem 277: 23807–23814.
11. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G (2007) Pyruvate kinase
deficiency: the genotype-phenotype association. Blood Rev 21: 217–231.
12. Loh WP (1968) A new solubility test for rapid detection of haemoglobin.
J Indiana State Med Assoc 61: 1651–1652.
13. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, et al. (2011) Duffy negative
antigen is no longer a barrier to Plasmodium vivax - molecular evidences from the
African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 5:
e1192.
14. Pinto J, Sousa CA, Gil V, Ferreira C, Gonc¸alves L, et al. (2000) Malaria in Sa˜o
Tome´ and Prı´ncipe: parasite prevalences and vector densities. Acta Trop 76:
185–193.
15. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN (1993)
Identification of the four human malaria parasite species in field samples by
the polymerase chain reaction and detection of a high prevalence of mixed
infections. Mol Biochem Parasitol 58: 283–292.
16. Beutler E (1984) Red Cell Metabolism: A Manual of Biochemical Methods.
Grune & Stratton, Philadelphia, PA.
17. Manco L, Ribeiro ML, Almeida H, Freitas O, Abade A, et al. (1999) PK-LR
gene mutations in pyruvate kinase deficient Portuguese patients. Br J Haematol
105: 591–595.
18. Simple Interactive Statistical Analysis software, SISA. Available: http://www.
quantitativeskills.com/sisa/. Accessed 2012 Jun 29.
19. Excoffier L, Laval G, Schneider S (2005) Arlequin (version 3.0): an integrated
software package for population genetics data analysis. Evol Bioinform Online 1:
47–50. Available: http://cmpg.unibe.ch/software/arlequin3/. Accessed 2012
Jun 29.
20. Polyphen software. Available: http://genetics.bwh.harvard.edu/php/. Accessed
2012 9 Aug 9.
21. The PyMOL Molecular Graphics System, Version 1.2r3pre, Schro¨dinger, LLC.
Available: http://www.pymol.org/. Accessed 2012 Jun 29.
22. Ministe´rio da Sau´de, Direcc¸a˜o Geral da Sau´de, Repu´blica de Moc¸ambique
(2002) Moc¸ambique: Investir na Nutric¸a˜o e´ Reduzir a Pobreza. Ana´lise das
Consequeˆncias dos Problemas Nutricionais nas Crianc¸as e Mulheres. Maputo.
23. Beutler E, Gelbart T (2000) Estimating the prevalence of pyruvate kinase
deficiency from the gene frequency in the general white population. Blood 95:
3585–3588.
24. Carey PJ, Chandler J, Hendrick A, Reid MM, Saunders PW, et al. (2000)
Prevalence of pyruvate kinase deficiency in northern European population in the
north of England. Northern Region Haematologists Group. Blood 96: 4005–
4006.
25. Garcı´a SC, Morago´n AC, Lo´pez-Ferna´ndez ME (1979) Frequency of
glutathione reductase, pyruvate kinase and glucose-6-phosphate dehydrogenase
deficiency in a Spanish population. Hum Hered 29: 310–313.
26. Akin H, Baykal-Erkilic¸ A, Aksu A, Yu¨cel G, Gu¨mu¨s¸lu¨ S (1997) Prevalence of
erythrocyte pyruvate kinase deficiency and normal values of enzyme in a
Turkish population. Hum Hered 47: 42–46.
27. Feng CS, Tsang SS, Mak YT (1993) Prevalence of pyruvate kinase deficiency
among the Chinese: determination by the quantitative assay. Am J Hematol 43:
271–273.
28. Yavarian M, Karimi M, Shahriary M, Afrasiabi AR (2008) Prevalence of
pyruvate kinase deficiency among the south Iranian population: quantitative
assay and molecular analysis. Blood Cells Mol Dis 40: 308–311.
29. Abu-Melha AM, Ahmed MA, Knox-Macaulay H, Al-Sowayan SA, el-Yahia A
(1991) Erythrocyte pyruvate kinase deficiency in newborns of eastern Saudi
Arabia. Acta Haematol 85: 192–194.
30. Berghout J, Higgins S, Loucoubar C, Sakuntabhai A, Kain KC, et al. (2012)
Genetic diversity in human erythrocyte pyruvate kinase. Genes Immun 13: 98–
102.
31. Fung RH, Keung YK, Chung GS (1969) Screening of pyruvate kinase deficiency
and G6PD deficiency in Chinese newborn in Hong Kong. Arch Dis Child 44:
373–376.
32. University Medical Center. (2007) PKLR Mutation Database. Laboratory for
Red Blood Cel l Research : Ul trecht . Ava i lab le : ht tp ://www.
pklrmutationdatabase.com/. Accessed 2012 Jun 29.
33. WHO EMRO (2011) World Health Organization, Regional Office of the
Eastern Mediterranean, Epidemiological Situation, Country Profiles. Available:
http://www.emro.who.int/rbm/CountryProfiles-pak.htm. Accessed 2012 Jun
29.
PK Deficiency in Sub-Saharan Africa
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e47071
